|Application ||WB, IHC-P, IF, E|
|Other Accession||NP_000032, 348|
|Reactivity||Human, Mouse, Rat|
|Calculated MW||Predicted: 35 kDa |
Observed: 34 kDa
|Application Notes||APO-E antibody can be used for detection of APO-E by Western blot at 1 - 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 5 μg/mL. For immunofluorescence start at 20 μg/mL.|
|Target/Specificity||APO-E antibody was raised against a 19 amino acid peptide near the carboxy terminus of human APO-E.|
The immunogen is located within amino acids 220 - 270 of APO-E.
|Reconstitution & Storage||APO-E antibody can be stored at 4℃ for three months and -20℃, stable for up to one year.|
|Precautions||APO-E Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Mediates the binding, internalization, and catabolism of lipoprotein particles. It can serve as a ligand for the LDL (apo B/E) receptor and for the specific apo-E receptor (chylomicron remnant) of hepatic tissues.|
|Tissue Location||Occurs in all lipoprotein fractions in plasma. It constitutes 10-20% of very low density lipoproteins (VLDL) and 1-2% of high density lipoproteins (HDL). APOE is produced in most organs. Significant quantities are produced in liver, brain, spleen, lung, adrenal, ovary, kidney and muscle|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
APO-E Antibody: Chylomicron remnants and very low density lipoprotein (VLDL) remnants are rapidly removed from the circulation by receptor-mediated endocytosis in the liver. Apolipoprotein E (APO-E), a main apoprotein of the chylomicron, binds to a specific receptor on liver cells and peripheral cells and is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. Defects in APO-E result in familial dysbetalipoproteinemia, or type III hyperlipoproteinemia (HLP III), in which increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron and VLDL remnants.
Vasquez EC, Peotta VA, Gava TMC, et al. Cardiac and vascular phenotypes in the epolipoprotein E-deficient mouse. J. Biomed. Sci. 2012; 19:22.
Feussner G, Funke H, Weng W, et al. Severe type III hyperlipoproteinemia associated with unusual apolipoprotein E1 phenotype and epsilon 1/’null’ genotype. Eur. J. Clin. Invest. 1992; 22:599-608.
If you have any additional inquiries please email technical services at email@example.com.